"Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism": Reply

J Thromb Haemost. 2022 Jul;20(7):1748-1749. doi: 10.1111/jth.15737.

Authors

Ingrid M Bistervels^{1

2}, Roisin Bavalia^{1

2}, Saskia Middeldorp^{1

2

3}, Michiel Coppens^{1

2}

Affiliations

¹ Vascular Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
² Pulmonary Hypertension & Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
³ Department of Internal Medicine, Radboud Institute of Health Sciences (RIHS), Radboud university medical center, Nijmegen, The Netherlands.

PMID: 35754011
DOI: 10.1111/jth.15737

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants / adverse effects
Factor Xa Inhibitors / adverse effects
Fibrinolytic Agents / therapeutic use
Hemorrhage / chemically induced
Hemorrhage / drug therapy
Humans
Polypharmacy
Rivaroxaban / adverse effects
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / drug therapy
Vitamin K

Substances

Anticoagulants
Factor Xa Inhibitors
Fibrinolytic Agents
Vitamin K
Rivaroxaban